We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.33 | -0.36% | 91.57 | 91.56 | 91.58 | 92.24 | 91.51 | 91.83 | 338,661 | 14:46:14 |
From May 2019 to May 2024
French drugs company Sanofi-Aventis (SNY) Monday said it has reshuffled its executive committe, adding the head of its vaccines division Wayne Pisano and widening the scope of pharmaceutical operations Executive Vice President Hanspeter Spek's duties to cover global operations.
In a press release, Sanofi Chief Executive Chris Viehbacher said he has promoted Marc Cluzel from senior vice president of research and development to executive vice president of the division, citing "the strategic importance of transforming" the division.
Under Viehbacher's lead, Sanofi has been paring its R&D projects and focusing on developing partnerships with outside firms to beef up products in the development pipeline.
The company's executive committee will meet twice a month, Sanofi said in the statement.
Company Web site: www.sanofi-aventis.com
-By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 17 73; mimosa.spencer@dowjones.com
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
